
==== Front
Cancer Med
Cancer Med
10.1002/(ISSN)2045-7634
CAM4
Cancer Medicine
2045-7634
John Wiley and Sons Inc. Hoboken

10.1002/cam4.70174
CAM470174
Correction
Correction
Correction to “Structure‐based pharmacophore modeling for precision inhibition of mutant ESR2 in breast cancer: A systematic computational approach”
09 9 2024
9 2024
09 9 2024
13 17 10.1002/cam4.v13.17 e70174© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

10.1002/cam4.70074 source-schema-version-number2.0
cover-dateSeptember 2024
details-of-publishers-convertorConverter:WILEY_ML3GV2_TO_JATSPMC version:6.4.8 mode:remove_FC converted:09.09.2024
==== Body
pmcIslam S, Amin MA, Rengasamy KRR, Mohiuddin AKM, Mahmud S. Structure‐based pharmacophore modeling for precision inhibition of mutant ESR2 in breast cancer: A systematic computational approach. Cancer Med. 2024;13(15):e70074. doi:10.1002/cam4.70074.

A second affiliation has been added for Kannan R. R. Rengasamy and reads as follows:

3Centre of Excellence for Pharmaceutical Sciences, North‐West University, Potchefstroom, 2520, South Africa.

An acknowledgment section has been added and reads as follows:

Kannan R.R. Rengasamy acknowledges the Centre for High Performance Computing (CHPC), South Africa, for providing computational resources to this research project.

We apologize for this error.
